NAVIDEA BIOPHARMACEUTICALS, INC.
DelistedCIK 810509fmd_0QXF3FW726K0BVVWRQQH6VG8S8Manufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2023, 55 periods
Latest annual · FY2022
Millions- Total revenues
- 0
- Gross profit
- (0)
- Operating income
- (14)
- Net income
- (15)
- Free cash flow
- (9)
Latest quarter · Q3 FY2023
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (2)
- Net income
- (2)
- Free cash flow
- (10)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2019 to FY2022
- -53.6%
- Revenue, 5 yearsFY2017 to FY2022
- -48.5%
- Net income, 5 yearsFY2017 to FY2022
- n/m
NAVIDEA BIOPHARMACEUTICALS, INC. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Revenue | $65,652 | $531,513 | -87.6% | 10-K 2023-03-27 · proof |
| Gross profit | -$119,295 | $531,513 | -122.4% | 10-K 2023-03-27 · proof |
| Operating income | -$14.1 million | -$12.1 million | 10-K 2023-03-27 · proof | |
| Net income | -$15.2 million | -$11.7 million | 10-K 2023-03-27 · proof | |
| Cash from operating activities | -$9 million | -$10.2 million | 10-K 2023-03-27 · proof | |
| Free cash flow | -$9 million | -$10.2 million | 10-K 2023-03-27 · proof | |
| Total assets | $4.4 million | $6.6 million | -34.2% | 10-K 2023-03-27 · proof |
| Total liabilities | $12.5 million | $6 million | +107.9% | 10-K 2023-03-27 · proof |
| Cash and cash equivalents | $2 million | $4.2 million | -52.8% | 10-K 2023-03-27 · proof |
- What was NAVIDEA BIOPHARMACEUTICALS, INC.'s revenue in fiscal 2022?
- NAVIDEA BIOPHARMACEUTICALS, INC. reported revenue of $65,652 for fiscal 2022 (the year ended Dec 31, 2022), against $531,513 the year before (-87.6%). Source: the 10-K filed with the SEC on Mar 27, 2023. SEC
- What was NAVIDEA BIOPHARMACEUTICALS, INC.'s gross profit in fiscal 2022?
- NAVIDEA BIOPHARMACEUTICALS, INC. reported gross profit of -$119,295 for fiscal 2022 (the year ended Dec 31, 2022), against $531,513 the year before (-122.4%). Source: the 10-K filed with the SEC on Mar 27, 2023. SEC
- What was NAVIDEA BIOPHARMACEUTICALS, INC.'s operating income in fiscal 2022?
- NAVIDEA BIOPHARMACEUTICALS, INC. reported operating income of -$14.1 million for fiscal 2022 (the year ended Dec 31, 2022), against -$12.1 million the year before. Source: the 10-K filed with the SEC on Mar 27, 2023. SEC
- What was NAVIDEA BIOPHARMACEUTICALS, INC.'s net income in fiscal 2022?
- NAVIDEA BIOPHARMACEUTICALS, INC. reported net income of -$15.2 million for fiscal 2022 (the year ended Dec 31, 2022), against -$11.7 million the year before. Source: the 10-K filed with the SEC on Mar 27, 2023. SEC
- What was NAVIDEA BIOPHARMACEUTICALS, INC.'s cash from operating activities in fiscal 2022?
- NAVIDEA BIOPHARMACEUTICALS, INC. reported cash from operating activities of -$9 million for fiscal 2022 (the year ended Dec 31, 2022), against -$10.2 million the year before. Source: the 10-K filed with the SEC on Mar 27, 2023. SEC
- What was NAVIDEA BIOPHARMACEUTICALS, INC.'s free cash flow in fiscal 2022?
- NAVIDEA BIOPHARMACEUTICALS, INC. reported free cash flow of -$9 million for fiscal 2022 (the year ended Dec 31, 2022), against -$10.2 million the year before. Source: the 10-K filed with the SEC on Mar 27, 2023. SEC
- What are NAVIDEA BIOPHARMACEUTICALS, INC.'s total assets?
- As of Dec 31, 2022, NAVIDEA BIOPHARMACEUTICALS, INC. reported total assets of $4.4 million, against $6.6 million a year earlier (-34.2%). Source: the 10-K filed with the SEC on Mar 27, 2023. SEC
- What are NAVIDEA BIOPHARMACEUTICALS, INC.'s total liabilities?
- As of Dec 31, 2022, NAVIDEA BIOPHARMACEUTICALS, INC. reported total liabilities of $12.5 million, against $6 million a year earlier (+107.9%). Source: the 10-K filed with the SEC on Mar 27, 2023. SEC
- What are NAVIDEA BIOPHARMACEUTICALS, INC.'s cash and cash equivalents?
- As of Dec 31, 2022, NAVIDEA BIOPHARMACEUTICALS, INC. reported cash and cash equivalents of $2 million, against $4.2 million a year earlier (-52.8%). Source: the 10-K filed with the SEC on Mar 27, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:810509&period_type=annual&limit=5"Information only, not investment advice.